Recipharm’s new analytical lab brings impressive testing capabilities to global markets
Global contract development and manufacturing organisation (CDMO) Recipharm has opened a new analytical lab in Bengaluru, India to enhance its global testing capabilities for nitrosamines, extractables and leachables, and elemental impurity testing.
Fully cGMP/cGLP compliant, the 5,000 sq.ft lab will expand Recipharm’s existing analytical capabilities and provide support for biotech and pharma customers in their research and development of oral solids, drug delivery, inhalation, vaccines and injectables.
The investment in the new lab responds to the increasing demand for a trusted testing services partner. Filling a critical gap in the market, the lab will ensure product safety, regulatory compliance, consumer protection and patient well-being are considered in each project.
With new testing capabilities, Recipharm now provides customers with accurate and reliable testing services, method development and validation, and batch release testing of excipients, drug substance, drug product and container closure systems.
Gregor Kawaletz, Head of Business Unit OSD at Recipharm, said: “The launch of Recipharm’s new analytical lab marks a new era in cutting-edge laboratory techniques for us as a Group. This key milestone represents our commitment to staying at the forefront of analytical technologies, ensuring that safety and quality of pharmaceutical and biopharmaceutical products is at the core of everything we do. With innovative methodologies and unmatched expertise, this new lab makes Recipharm a trusted partner for those seeking reliable solutions to ensure product safety and compliance for their projects. We are excited about the opportunities this lab will bring and look forward to continuing to service our clients with analytical testing excellence and reliability.”
Recipharm continues to focus its efforts on expanding both its facilities and its workforce, with 30 new and experienced research scientists commencing work at the lab which is now fully operational.
Contact information
For media enquiries, please contact Imogen Quail, imogen.quail@ramarketingpr.com, +44 (0)191 222 1242
About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical and biopharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical and biologics product development, and development and manufacturing of medical devices. Recipharm manufactures several hundred different products for customers ranging from big pharma to smaller research and development companies. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden.
For more information on Recipharm and our services, please visit www.recipharm.com
Recipharm AB │ Corporate ID 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden │ Telephone +46 8 602 52 00
www.recipharm.com
Tags: